Fatigue and related factors after liver transplantation.
10.14701/kjhbps.2015.19.4.149
- Author:
Kwangpyo HONG
1
;
Hyeyoung KIM
;
Jeong Moo LEE
;
Kwang Woong LEE
;
Nam Joon YI
;
Hae Won LEE
;
Youngrok CHOI
;
Suk Won SUH
;
Suk Kyun HONG
;
Kyung Chul YOON
;
Hyo Sin KIM
;
Kyung Suk SUH
Author Information
1. Department of Surgery, Seoul National University College of Medicine, Seoul, Korea. kssuh@snu.ac.kr
- Publication Type:Original Article
- Keywords:
Liver transplantation;
Fatigue;
Risk factors;
Complications
- MeSH:
Adult;
Ambulatory Care Facilities;
Carcinoma, Hepatocellular;
Fatigue*;
Follow-Up Studies;
Hepatitis B;
Hepatitis, Chronic;
Humans;
Liver Diseases;
Liver Transplantation*;
Liver*;
Living Donors;
Male;
Prevalence;
Retrospective Studies;
Risk Factors
- From:Korean Journal of Hepato-Biliary-Pancreatic Surgery
2015;19(4):149-153
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUNDS/AIMS: Fatigue is common in chronic hepatitis and end-stage liver disease. However, little is known about fatigue after liver transplantation (LT). We therefore evaluated the prevalence, severity, and related factors of fatigue after LT. METHODS: We retrospectively reviewed adult recipients who responded to our survey at outpatient clinics between April and May 2013. Fatigue and its severity were assessed using a questionnaire with the Fatigue Severity Scale (FSS). We defined fatigue as FSS of 4.0 or more and severe fatigue as FSS of 5.1 or more. The related factors including hepatocellular carcinoma and complications were analyzed. RESULTS: A total of 93 patients were included in this study. The mean age was 54.9 (19-76) years and two-thirds were men (67.7%). Living donor LT was 77.4%. Hepatitis B related liver disease was the main underlying disease (77.4%), with hepatocellular carcinoma accompanied in 33.3%. The mean follow-up period was 66.8+/-43.2 (2-171) months. The mean FFS was 2.83+/-1.48 (1.0-6.7) overall and 5.10+/-0.82 (4.0-6.7) in the fatigue group. Of the 93 adult patients, fatigue was presented in 20 patients (21.5%). Among these, 9 patients (45.0%) showed severe fatigue. Even though post-LT complications tended to be greater in the fatigue group (50.0% vs. 30.1% in the non-fatigue group, p=0.098), there were no significant related factors of fatigue after LT, including hepatocellular carcinoma and major complication. CONCLUSIONS: Fatigue is present in a considerable portion of recipients after LT, and almost half of them have severe fatigue. Further efforts are needed to decrease fatigue in LT recipients.
